Brian D Weiss1, Gregory Yanik2, Arlene Naranjo3, Fan F Zhang4, Wendy Fitzgerald5, Barry L Shulkin6, Marguerite T Parisi7, Heidi Russell8, Stephan Grupp9, Luke Pater1, Peter Mattei9, Yael Mosse9, Hollie A Lai10, Jason A Jarzembowski11, Hiroyuki Shimada12, Judith G Villablanca13, Roger Giller14, Rochelle Bagatell9, Julie R Park15, Katherine K Matthay16. 1. Cincinnati Children's Hospital, University of Cincinnati School of Medicine Cincinnati, Ohio. 2. CS Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, Michigan. 3. Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, Florida. 4. Children's Oncology Group Statistics and Data Center, Monrovia, California. 5. Children's National Health System, District of Columbia, Washington. 6. St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Memphis, Tennessee. 7. Seattle Children's Hospital, Seattle, Washington. 8. Texas Children's Cancer and Hematology Centers, Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas. 9. Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 10. Children's Hospital of Orange County, Orange, California. 11. Midwest Children's Cancer Center, Milwaukee, Wisconsin. 12. Lucille Packards Children's Hospital, Palo Alto, California. 13. Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California. 14. Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado. 15. Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington. 16. UCSF Benioff Children's Hospital, University of California San Francisco School of Medicine, San Francisco, California.
Abstract
INTRODUCTION: 131 I-meta-iodobenzylguanidine (131 I-MIBG) is effective in relapsed neuroblastoma. The Children's Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by 131 I- MIBG therapy and myeloablative busulfan/melphalan (Bu/Mel) in patients with newly diagnosed high-risk neuroblastoma. METHODS: Patients with MIBG-avid high-risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re-designed to include an 131 I-MIBG dose escalation (12, 15, and 18 mCi/kg), with a required 10-week gap before Bu/Mel administration. Patients who completed induction chemotherapy were evaluable for assessment of 131 I-MIBG feasibility; those who completed 131 I-MIBG therapy were evaluable for assessment of 131 I-MIBG + Bu/Mel feasibility. RESULTS: Fifty-nine of 68 patients (86.8%) who completed induction chemotherapy received 131 I-MIBG. Thirty-seven of 45 patients (82.2%) evaluable for 131 I-MIBG + Bu/Mel received this combination. Among those who received 131 I-MIBG after revision of the study design, one patient per dose level developed severe SOS. Rates of moderate to severe SOS at 12, 15, and 18 mCi/kg were 33.3%, 23.5%, and 25.0%, respectively. There was one toxic death. The 131 I-MIBG and 131 I-MIBG+Bu/Mel feasibility rates at the 15 mCi/kg dose level designated for further study were 96.7% (95% CI: 83.3%-99.4%) and 81.0% (95% CI: 60.0%-92.3%). CONCLUSION: This pilot trial demonstrated feasibility and tolerability of administering 131 I-MIBG followed by myeloablative therapy with Bu/Mel to newly diagnosed children with high-risk neuroblastoma in a cooperative group setting, laying the groundwork for a cooperative randomized trial (NCT03126916) testing the addition of 131 I-MIBG during induction therapy.
INTRODUCTION: 131 I-meta-iodobenzylguanidine (131 I-MIBG) is effective in relapsed neuroblastoma. The Children's Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by 131 I- MIBG therapy and myeloablative busulfan/melphalan (Bu/Mel) in patients with newly diagnosed high-risk neuroblastoma. METHODS: Patients with MIBG-avid high-risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re-designed to include an 131 I-MIBG dose escalation (12, 15, and 18 mCi/kg), with a required 10-week gap before Bu/Mel administration. Patients who completed induction chemotherapy were evaluable for assessment of 131 I-MIBG feasibility; those who completed 131 I-MIBG therapy were evaluable for assessment of 131 I-MIBG + Bu/Mel feasibility. RESULTS: Fifty-nine of 68 patients (86.8%) who completed induction chemotherapy received 131 I-MIBG. Thirty-seven of 45 patients (82.2%) evaluable for 131 I-MIBG + Bu/Mel received this combination. Among those who received 131 I-MIBG after revision of the study design, one patient per dose level developed severe SOS. Rates of moderate to severe SOS at 12, 15, and 18 mCi/kg were 33.3%, 23.5%, and 25.0%, respectively. There was one toxic death. The 131 I-MIBG and 131 I-MIBG+Bu/Mel feasibility rates at the 15 mCi/kg dose level designated for further study were 96.7% (95% CI: 83.3%-99.4%) and 81.0% (95% CI: 60.0%-92.3%). CONCLUSION: This pilot trial demonstrated feasibility and tolerability of administering 131 I-MIBG followed by myeloablative therapy with Bu/Mel to newly diagnosed children with high-risk neuroblastoma in a cooperative group setting, laying the groundwork for a cooperative randomized trial (NCT03126916) testing the addition of 131 I-MIBG during induction therapy.
Authors: Navin Pinto; Arlene Naranjo; Emily Hibbitts; Susan G Kreissman; M Meaghan Granger; Meredith S Irwin; Rochelle Bagatell; Wendy B London; Emily G Greengard; Julie R Park; Steven G DuBois Journal: Eur J Cancer Date: 2019-04-01 Impact factor: 9.162
Authors: Mark N Fluchel; Anne C Kirchhoff; Julia Bodson; Carol Sweeney; Sandra L Edwards; Qian Ding; Gregory J Stoddard; Anita Y Kinney Journal: Pediatr Blood Cancer Date: 2014-08-17 Impact factor: 3.167
Authors: Gregory A Yanik; John E Levine; Katherine K Matthay; James C Sisson; Barry L Shulkin; Brahm Shapiro; David Hubers; Susan Spalding; Tom Braun; James L M Ferrara; Raymond J Hutchinson Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: T Klingebiel; P Bader; R Bares; J Beck; B Hero; H Jürgens; P Lang; D Niethammer; B Rath; R Handgretinger Journal: Eur J Cancer Date: 1998-08 Impact factor: 9.162
Authors: Ruth Ladenstein; Bieke Lambert; Ulrike Pötschger; Maria-Rita Castellani; Valerie Lewington; Zvi Bar-Sever; Aurore Oudoux; Anna Śliwińska; Katerina Taborska; Lorenzo Biassoni; Gregory A Yanik; Arlene Naranjo; Marguerite T Parisi; Barry L Shulkin; Helen Nadel; Michael J Gelfand; Katherine K Matthay; Julie R Park; Susan G Kreissman; Dominique Valteau-Couanet; Ariane Boubaker Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-23 Impact factor: 9.236
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; Minna Koskenvuo; Jelena Rascon; Max van Noesel; Per Grybäck; Joachim Nilsson; Arthur Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Dan Granberg; Mark Gaze; Jakob Stenman Journal: Front Pediatr Date: 2022-03-10 Impact factor: 3.418